Jump to content

TACSTD2

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Tom.Reding (talk | contribs) at 23:06, 3 June 2016 (CS1 maintenance: vauthors/veditors or enumerate multiple authors/editors; WP:GenFixes on, fix author per pmid using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

TACSTD2
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesTACSTD2, EGP-1, EGP1, GA733-1, GA7331, GP50, M1S1, TROP2, tumor-associated calcium signal transducer 2, tumor associated calcium signal transducer 2
External IDsOMIM: 137290; MGI: 1861606; HomoloGene: 1763; GeneCards: TACSTD2; OMA:TACSTD2 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_002353

NM_020047

RefSeq (protein)

NP_002344

NP_064431

Location (UCSC)Chr 1: 58.58 – 58.58 MbChr 6: 67.51 – 67.51 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Tumor-associated calcium signal transducer 2, also known as Trop-2 and as epithelial glycoprotein-1 antigen (EGP-1),[5] is a protein that in humans is encoded by the TACSTD2 gene.[6][7][8]

This intronless gene encodes a carcinoma-associated antigen defined by the monoclonal antibody GA733. This antigen is a member of a family including at least two type I membrane proteins. It transduces an intracellular calcium signal and acts as a cell surface receptor.

Mutations of this gene result in gelatinous drop-like corneal dystrophy, an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness.[8]

This antigen is the target of sacituzumab govitecan, an antibody-drug conjugate.

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000184292Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000051397Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Immunomedics Awarded Fast Track Designation by FDA for Sacituzumab Govitecan (IMMU-132) for Triple-Negative Breast Cancer Therapy [1]
  6. ^ Linnenbach AJ, Seng BA, Wu S, Robbins S, Scollon M, Pyrc JJ, Druck T, Huebner K (Apr 1993). "Retroposition in a family of carcinoma-associated antigen genes". Mol Cell Biol. 13 (3): 1507–15. PMC 359462. PMID 8382772.
  7. ^ Calabrese G, Crescenzi C, Morizio E, Palka G, Guerra E, Alberti S (Apr 2001). "Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization". Cytogenet Cell Genet. 92 (1–2): 164–5. doi:10.1159/000056891. PMID 11306819.
  8. ^ a b "Entrez Gene: TACSTD2 tumor-associated calcium signal transducer 2".

Further reading

Template:PBB Controls